SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-20-056208
Filing Date
2020-12-04
Accepted
2020-12-04 17:10:30
Documents
15
Period of Report
2020-12-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K srne-8k_20201204.htm   iXBRL 8-K 46048
2 EX-1.1 srne-ex11_6.htm EX-1.1 27200
3 EX-5.1 srne-ex51_18.htm EX-5.1 10069
4 GRAPHIC g5vhuszlpa5t000001.jpg GRAPHIC 11200
  Complete submission text file 0001564590-20-056208.txt   234103

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA srne-20201204.xsd EX-101.SCH 5736
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE srne-20201204_lab.xml EX-101.LAB 18910
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE srne-20201204_pre.xml EX-101.PRE 11130
8 EXTRACTED XBRL INSTANCE DOCUMENT srne-8k_20201204_htm.xml XML 3418
Mailing Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121
Business Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121 858-203-4100
Sorrento Therapeutics, Inc. (Filer) CIK: 0000850261 (see all company filings)

IRS No.: 330344842 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36150 | Film No.: 201370611
SIC: 2836 Biological Products, (No Diagnostic Substances)